Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
10.1074/jbc.M113.545301 J
Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
developed a biomimetic nanomodulator targeting sepsis-associated encephalopathy, which crossed the blood-brain barrier, alleviated oxidative stress, polarized macrophages toward anti-inflammatory phenotypes, and improved cognition and survival (Qu et al., 2024)
Munday, R., and Winterbourn, C
Medications are purchased from licensed pharmacies
Tirzepatide does not increase the risk of hypoglycemia when used as monotherapy
US$ 27.55
US$ 26.51
US$ 24.39
US$ 27.61
US$ 26.65
